Evidence map›Paper›PMID 31746553›Full record

ArticleObesity (Silver Spring, Md.)2019

Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology.

Ariana M Chao, Thomas A Wadden, Olivia A Walsh, Kathryn A Gruber, Naji Alamuddin, Robert I Berkowitz, Jena S Tronieri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity (Silver Spring, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. GLP-1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Observational
  13. Review
  14. Pharmacological management of binge eating disorder.The mental health clinician · 2025
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ariana M ChaoDepartment of Biobehavioral Health Sciences, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-5633-8973
Thomas A WaddenDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-0438-4609
Olivia A WalshDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kathryn A GruberDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Naji AlamuddinDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Robert I BerkowitzDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jena S TronieriDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

Neural response to food stimuli: fMRI changes following cognitive behavioral therapy for binge eating disorderK23NR017209 · NINR · UNIVERSITY OF PENNSYLVANIA · PI CHAO, ARIANA MARIE · 2018 to 2020
$520k
NINR NIH HHS K23 NR017209
6 · The paper itself

Abstract

objectiveThis exploratory analysis examined the effects of intensive behavioral therapy (IBT) for obesity ("IBT-alone"), IBT plus liraglutide 3.0 mg/d ("IBT-liraglutide"), and IBT plus liraglutide 3.0 mg/d plus 12 weeks of a portion-controlled diet that provided 1,000 to 1,200 kcal/d ("Multicomponent") on changes in food cravings, eating behaviors, and eating disorder psychopathology at 24 and 52 weeks post randomization.

methodsAdults with obesity (mean age = 47.6 ± 11.8 years and BMI = 38.4 ± 4.9 kg/m

resultsAt weeks 24 and 52, liraglutide-treated groups reported significantly larger declines in weight concern relative to the IBT-alone group. At week 24, compared with IBT-alone, liraglutide-treated groups reported significantly greater reductions in dietary disinhibition, global eating disorder psychopathology, and shape concern. The Multicomponent group had significantly greater reductions in binge eating at week 24 relative to the IBT-alone group. However, differences among groups were no longer significant at week 52. Groups did not differ in total food cravings at week 24 or 52.

conclusionsThe combination of liraglutide and IBT was associated with greater short-term improvements in dietary disinhibition, global eating disorder psychopathology, and shape concern than IBT alone.

Indexed as

Anti-Obesity AgentsBehavior TherapyBinge-Eating DisorderCravingFeeding and Eating DisordersFemaleHumansHypoglycemic AgentsLiraglutideMaleMiddle AgedObesityPsychopathologyTreatment OutcomeWeight LossAnti-Obesity AgentsHypoglycemic AgentsLiraglutide

Identifiers

PMID31746553
PMCPMC6873814

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.